Stock Monitor: AstraZeneca Post Earnings Reporting
LONDON, UK / ACCESSWIRE / January 05, 2018 / Active-Investors.com has just released a free research report on Myriad Genetics, Inc. (NASDAQ: MYGN) ("Myriad"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=MYGN as the Company's latest news hit the wire. On January 03, 2017, the Company, a leading molecular diagnostics and personalized medicine organization, declared that it has entered into an expanded research collaboration agreement with AstraZeneca PLC (NYSE: AZN). As per the agreement, AstraZeneca will use Myriad's myChoice HRD Plus in an exploratory analysis to diagnose women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab). The financial terms of the deal were, however, not disclosed by the Companies. Register today and get access to over 1000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Myriad Genetics and AstraZeneca most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/'symbol=MYGN
www.active-investors.com/registration-sg/'symbol=AZN
Ovarian Cancer Needs Regular Screening
Ovarian cancer is a cancer that begins in the female organs that produce eggs (ovaries). Women in all life stages are at risk of developing ovarian cancer. This form of cancer has the lowest survival rate of all female cancers - it is responsible for about 140,000 deaths each year. Every year, a quarter of a million women are diagnosed of ovarian cancer globally, of which, only 45% are likely to survive for five years.
The main issue with this form of cancer is that patients are identified in the advanced stages when the disease becomes more difficult to treat and sometimes fatal. Women should therefore get themselves checked regularly.
About myChoice HRD Plus
Myriad's myChoice HRD Plus is a comprehensive homologous recombination deficiency test which helps to detect when the tumor loses the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The myChoice HRD Plus test comprises of three proprietary technologies, namely: (i) loss of heterozygosity, (ii) telomeric allelic imbalance, and (iii) large-scale state transitions. Other than that, it also includes 90 other genes and molecular markers including microsatellite instability associated with DNA repair pathways.
Positive myChoice HRD Plus scores, which indicate DNA repair deficiencies, are present in all breast cancer subtypes, ovarian cancer, and other major cancers. In fact, approximately 1.4 million people in the United States and Europe who are diagnosed with cancers every year could be candidates for treatment with DNA-damaging agents.
About Lynparza
Lynparza (olaparib) is a type of targeted therapy for ovarian cancer. It is an innovative, first-in-class oral poly ADP-ribose polymerase (PARP) inhibitor that uses tumor DNA damage response (DDR) pathway deficiencies to kill cancer cells. Lynparza is the foundation of AstraZeneca's industry-leading portfolio of compounds targeting DDR mechanisms in cancer cells. In July 2017, AstraZeneca entered into a global strategic oncology collaboration agreement with Merck & Co., Inc., Kenilworth, NJ, USA, to jointly co-develop and co-commercialize Lynparza.
At present, Lynparza has been approved in the United States for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in response to platinum-based chemotherapy, and for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Besides, regulatory health authorities in the European Union (EU) have also approved Lynparza for use as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer, for those who are in response to platinum-based chemotherapy.
MyChoice HRD Plus to Be Used as a Potential Companion Diagnostic in Lynparza Clinical Trial
As per the agreement, Myriad will use its myChoice HRD Plus test to evaluate patients enrolled in the ongoing Phase-III trial of AstraZeneca's PARP inhibitor Lynparza. The HRD Plus test will be used to identify cases with homologous recombination deficiencies (HRD). As a result, more people will benefit from therapy with Lynparza than previous tests that only identified germline BRCA1/2 mutations.
This ongoing collaboration with AstraZeneca to develop a novel companion diagnostic test to identify candidates for treatment with olaparib started back in 2007. Myriad got the US Food and Drug Administration (FDA)'s approval for BRACAnalysis CDx to help identify patients with advanced ovarian cancer who are eligible for fourth-line treatment with olaparib in December 2014. BRACAnalysis CDx was Myriad's first FDA-approved companion diagnostic and was the first-ever laboratory developed test approved by the FDA.
Stock Performance Snapshot
January 04, 2018 - At Thursday's closing bell, Myriad Genetics' stock dropped 2.05%, ending the trading session at $34.38.
Volume traded for the day: 461.46 thousand shares.
Stock performance in the last month - up 2.54%; previous six-month period - up 35.67%; past twelve-month period - up 95.12%; and year-to-date - up 0.10%
After yesterday's close, Myriad Genetics' market cap was at $2.40 billion.
Price to Earnings (P/E) ratio was at 23.17.
The stock is part of the Services sector, categorized under the Research Services industry. This sector was up 0.1% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
